Published online before print May 13, 2002, doi: 10.1161/01.CIR.0000017493.03108.1C
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2002;105:2595.)
© 2002 American Heart Association, Inc.
Clinical Investigation and Reports |
Prospective Study of C-Reactive Protein, Homocysteine, and Plasma Lipid Levels as Predictors of Sudden Cardiac Death
From the Center for Cardiovascular Disease Prevention, Division of Preventive Medicine, Leducq Center for Molecular and Genetic Epidemiology (C.M.A, P.M.R), and Channing Laboratory (J.M., M.J.S.), Department of Medicine, Brigham and Women’s Hospital, Boston; the Cardiovascular Division (C.M.A.), Department of Medicine, Massachusetts General Hospital, Boston; the Departments of Epidemiology (M.J.S) and Nutrition (M.J.S.), Harvard School of Public Health, Boston; and the Departments of Laboratory Medicine and Pathology, Children’s Medical Center (N.R.), Harvard Medical School, Boston, Mass.
Reprint requests to Dr Christine M. Albert, Division of Preventive Medicine, Brigham and Women’s Hospital, 900 Commonwealth Ave East, Boston, MA 02215-1204.
 |
Abstract |
|---|
 Top Abstract IntroductionMethodsResultsDiscussionReferences |
|---|
Background— Sudden cardiac death (SCD) is an important cause of mortality even among apparently healthy populations. However, our ability to identify those at risk for SCD in the general population is poor, and more specific markers are needed.
Methods and Results— To compare and contrast the relative importance of C-reactive protein (CRP), homocysteine, and lipids as long-term predictors of SCD, we performed a prospective, nested, case-control analysis involving 97 cases of SCD among apparently healthy men enrolled in the Physician’s Health Study. Of these plasma markers measured, only baseline CRP levels were significantly associated with the risk of SCD over the ensuing 17 years of follow-up (P for trend=0.001). The increase in risk associated with CRP levels was primarily seen among men in the highest quartile, who were at a 2.78-fold increased risk of SCD (95% CI 1.35 to 5.72) compared with men in the lowest quartile. These results were not significantly altered in analyses that (in addition to the matching variables of age and smoking status) controlled for lipid parameters, homocysteine, and multiple cardiac risk factors (relative risk for highest versus lowest quartile 2.65, 95% CI 0.79 to 8.83; P for trend=0.03). In contrast to the positive relationship observed for CRP, neither homocysteine nor lipid levels were significantly associated with risk of SCD.
Conclusions— These prospective data suggest that CRP levels may be useful in identifying apparently healthy men who are at an increased long-term risk of SCD.
Key Words: death, sudden • inflammation • lipids • risk factors
|
Introduction |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
In the United States, 250 000 sudden cardiac deaths (SCDs) occur every year, constituting
50% of all coronary heart disease (CHD) deaths.1 Although the presence of overt CHD markedly increases the risk of SCD,2 over half of the SCD victims do not have clinically recognized CHD before death.3 CHD risk factors are predictive of SCD in this segment of the population; however, single risk factors, including lipids, are limited in their ability to identify specific individuals who are at high risk of SCD.3,4 Therefore, there is a need for additional markers of SCD risk.
See p 2574
Several novel risk factors for atherosclerosis have recently been proposed, including C-reactive protein (CRP) and homocysteine levels. Several lines of research indicate that chronic inflammation and thrombosis play a major role in the initiation and progression of atherosclerosis and in the conversion of a stable atherosclerotic plaque to an unstable potentially occlusive lesion. Markers of inflammation (most notably, CRP) have been found to predict future risk of myocardial infarction (MI) in several populations.5–7 Homocysteine, a nutritional marker associated with premature atherothrombosis, also predicts future risk of MI and CHD death in observational studies.8
Because atherosclerosis underlies most cases of SCD found in men9,10 and because acute plaque rupture with associated thrombosis is found in a significant proportion of SCD victims,11,12 CRP and/or homocysteine levels may aid in the identification of those at risk for SCD in apparently healthy populations. Although this use has been suggested for CRP, 13 neither hypothesis has been specifically examined. The Physicians’ Health Study of 22 071 apparently healthy men followed for an average of 17 years presented a unique opportunity to compare and contrast the potential value of CRP, homocysteine, and lipids as long-term predictors of SCD.
|
Methods |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
The methods of the Physicians’ Health Study have been described in detail elsewhere.14 Briefly, 22 071 male physicians who were aged 40 to 84 years in 1982 and who had no history of MI, stroke, transient ischemic attack, or cancer were assigned at random to aspirin, ß-carotene, both active drugs, or both placebos; a 2-by-2 factorial design was used. At baseline, the physicians completed questions on health status and risk factors for cardiovascular disease. Information on cardiovascular events was updated every 6 months for the first year and annually thereafter through brief follow-up questionnaires.
Before randomization, between August 1982 and December 1984, potential participants were asked to provide baseline blood samples, which were collected in EDTA and processed for long-term storage at -80°C. Of the randomized study participants, 14 916 (68%) provided baseline blood samples. At the time of blood collection, during the prerandomization run-in period, all study participants were taking active oral aspirin.
End-Point Confirmation and Selection of Controls
The end point of SCD was ascertained in a 2-step process. First, deaths of any cause were generally reported by postal authorities or next-of-kin and were confirmed for a cardiovascular cause through end-point committee review of medical records obtained from hospitals and attending physicians. Mortality follow-up was 99%. The next of kin was interviewed regarding the circumstances surrounding the death if it was not adequately documented in the medical records.
Second, to ascertain the specific end point of SCD, medical records and reports from next of kin for all cardiovascular deaths (excluding strokes) were reviewed again by 2 cardiologists unaware of exposure status. In this second review, SCD was defined as death within 1 hour of symptom onset and/or a witnessed cardiac arrest or abrupt collapse not preceded by >1 hour of symptoms that precipitated the terminal event. There was no other probable cause of death other than cardiac suggested by history or autopsy. To increase the specificity for "arrhythmic death," we excluded anyone who had evidence of collapse of the circulation (hypotension, exacerbation of congestive heart failure, and/or altered mental status) before the disappearance of the pulse.15 Unwitnessed deaths that could have occurred within 1 hour of symptom onset and that had autopsy findings consistent with an SCD (ie, acute coronary thrombosis or severe coronary artery disease without myocardial necrosis or other pathological findings to explain death) were considered probable SCDs.
Each participant who provided an adequate baseline blood sample for analysis and who had a confirmed SCD during follow-up was matched with 2 control subjects. Because relationships with MI have already been documented for both CRP6 and homocysteine16 in this cohort, we excluded those cases (n=22) with a documented MI, leaving 97 cases of SCD for this analysis. Controls were study participants with adequate baseline blood samples who were free of confirmed cardiovascular disease at the time of case ascertainment. Controls were randomly selected from the study participants who met the matching criteria of age (±1 year), length of study follow-up (6-month intervals), and smoking status (past smoking, current smoking, or never smoked). For 2 cases, only 1 adequate control could be found. With these criteria, 192 matched controls were evaluated in this analysis.
Measurement of CRP, Homocysteine, and Lipids
Baseline plasma samples were thawed and assayed for high-sensitivity CRP with the use of latex-enhanced immunonephelometric assays on a BN II analyzer (Dade Behring).17 Total cholesterol (TC), triglyceride, HDL cholesterol (HDL-C), and LDL cholesterol (LDL-C) levels were measured on a Hitachi 911 analyzer (Roche Diagnostics) with reagents from Roche Diagnostics and Genzyme. Plasma levels of homocysteine were measured by using high-performance liquid chromatography (Bio-Rad).18 Blood specimens were analyzed in blinded triplets, with the position of the case’s specimen varied at random within the triplets to reduce the possibility of systemic bias and to decrease interassay variability.
Statistical Analysis
Means or proportions for baseline cardiac risk factors were calculated for cases and controls. The significance of associations was tested with the 
2 statistic for categorical variables and with the Student t test for continuous variables. The median values for each plasma marker were first compared between case and control groups by using the nonparametric Wilcoxon rank sum test. After dividing the subjects into quartiles based on the distribution of control values, we then performed logistic regression analysis, conditioned on the matching variables of age and smoking, to compute the relative risks of SCD associated with increasing levels of CRP, lipid parameters, and homocysteine. Tests for trend for each plasma marker were performed by assigning the median value to each quartile and then modeling this as a continuous variable in separate conditional regression models.
For those plasma markers that were found to be associated with SCD in the age- and smoking-adjusted models, the conditional logistic regression model was adjusted further to determine the independent contribution of each plasma marker on the risk of SCD. First, the other plasma markers were entered simultaneously into the conditional logistic regression model to determine the independent effect of each marker (multivariate model 1). Then, the potential confounding variables of hypertension, body mass index, family history of premature atherosclerosis, diabetes, alcohol intake, and exercise frequency were added to this multivariate model (multivariate model 2). All probability values are 2-tailed, and all CIs were computed at the 95% level (SAS Version 8.2, SAS Institute).
|
Results |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Table 1 shows baseline characteristics of the 97 study subjects who died suddenly from cardiac causes (86 definite and 11 probable) and the 192 matched controls. The men who died suddenly were significantly more likely to have a history of hypertension and diabetes or a parental history of coronary artery disease. These men were also less likely to drink moderate amounts of alcohol or to have been randomized to aspirin. Because of matching, cases and controls were similar with respect to age and smoking status. The mean time to SCD was 9.2 years (range 0.7 to 16.8 years). As shown in Table 2, although there was some degree of overlap in the interquartile range, the median plasma level of CRP was significantly higher at baseline in cases than in controls (P=0.01). In contrast, the median homocysteine level was similar in cases and controls. Of the lipid parameters, only the TC/HDL-C ratio differed significantly between cases and controls (P=0.05).
|
|
Table 3 displays the relationship of baseline plasma levels of CRP, lipid parameters, and homocysteine to subsequent risk of SCD. Of the plasma markers measured, CRP was the most strongly associated with risk of SCD (P for trend<0.001). The increase in risk associated with CRP levels was primarily seen among men in the highest quartile, who were at a 2.78-fold increased risk of SCD (95% CI 1.35 to 5.72) compared with men in the lowest quartile. If we assume that the distribution of CRP levels in the controls is reflective of the entire cohort, 56% of the risk of SCD in this population would be estimated to be attributed to having a CRP level in the highest quartile (attributable risk percent). Again, the baseline homocysteine level was not related to subsequent risk of SCD. Of the lipid parameters, the TC/HDL-C ratio was the most strongly associated with the risk of SCD, although the P for trend value across quartiles was of borderline significance (P=0.06). Baseline plasma levels of TC, LDL-C, and triglycerides were not significantly associated with SCD risk.
|
On the basis of the results of the age- and smoking-adjusted analyses, we further evaluated the independent contribution of both CRP and TC/HDL-C ratio to SCD risk. The positive relationship between both of these variables and the risk of SCD was not materially altered in analyses that controlled for other plasma markers simultaneously (multivariate model 1, Table 4). CRP remained strongly associated with SCD risk (P for trend=0.004), and there continued to be a trend toward an increase in risk associated with the TC/HDL-C ratio (P for trend=0.09). When cardiac risk factors were additionally entered into the model (multivariate model 2, Table 4), the significant positive relationship between CRP levels and SCD persisted (P for trend=0.03); however, the relationship between TC/HDL-C was markedly attenuated and no longer approached significance (P for trend=0.28). Again the elevation in risk associated with CRP levels was primarily limited to the highest quartile. In a post hoc analysis, the men in the fourth quartile of CRP were compared with those in the lower 3 quartiles, and the multivariate relative risk of SCD in the highest quartile was significantly elevated at 2.79 (95% CI 1.06 to 7.34, P=0.04).
|
|
Discussion |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
In this prospective, nested, case-control study of apparently healthy male physicians, baseline plasma CRP levels were positively associated with risk of SCD over the ensuing 17 years of follow-up. The relationship remained significant even after controlling simultaneously for homocysteine, lipids, and multiple cardiac risk factors. Compared with men in the lowest quartile of CRP, the men in the highest quartile were at a 2.8-fold increased risk of SCD in age- and smoking-adjusted analyses, and these results were not materially altered in multivariate analyses. In contrast, neither homocysteine nor lipid levels were significantly associated with risk of SCD. Of the lipid parameters, the TC/HDL-C ratio was the most strongly associated with risk of SCD; however, this relationship was not significant in either the age- and smoking-adjusted or multivariate analysis.
These data raise both clinical and pathological issues. One clinical implication of these data is that markers of inflammation may be useful in identifying men at higher risk for SCD who have no obvious signs of CHD many years before the fatal event. Because >50% of all SCD victims do not have a history of clinically recognized CHD,3 improved identification of those at risk will hopefully improve our ability to prevent SCD. The observed long-term association between CRP and SCD also raises the possibility that intervention at an early stage in the development of disease process might be important for prevention. Individuals with elevated CRP levels, especially those in the highest quartile, might benefit from more aggressive long-term dietary, lifestyle, and coronary risk factor modification than would be the standard of care in a primary prevention population.
These data also raise important clues regarding the pathophysiological mechanism underlying the association between CRP and SCD. Given the length of time between the measurement of CRP and subsequent SCD in the present study (mean time to SCD was 9.2 years), it is likely that the effects of inflammation on SCD are mediated through a chronic process. The most obvious chronic process whereby inflammation may be involved in the pathogenesis of SCD is in the development of coronary atherosclerosis, which underlies 80% of all cases of SCD.9,10 CRP levels have been consistently associated with a variety of atherosclerotic end points in healthy populations6–7,19; however, none of these studies has examined the specific end point of SCD. One study of patients with angina pectoris found that CRP levels were directly correlated with the incidence of a combined end point of MI and SCD, but because of the small numbers of those experiencing SCD, that study was unable to examine the effect on this end point separately.20 In the present study, we excluded those cases (n=22) with a documented MI and, therefore, were able to specifically examine the end point of SCD independent of the known association with MI. Of note, the association between CRP and SCD was similar to that previously reported for MI,6 which is consistent with a common physiology underlying these 2 acute coronary syndromes.
Apart from their role in the development of underlying atherosclerosis, it is also possible that mediators of inflammation, such as CRP, may have direct long-term effects on ischemic, failing, or even normal myocardium that may be proarrhythmic. CRP levels have been associated with the development of arrhythmias in a small number of patients after coronary artery bypass surgery21 and with atrial fibrillation in a recently reported case-control study.22 Also, in autopsy cases of SCD for whom no macroscopic cause of death can be found, isolated areas of myocardial fibrosis and inflammation are often seen.23 These areas of inflammation and resulting fibrosis could predispose an individual to SCD by serving as a substrate for reentry. Finally, because markers of inflammation have also been associated with congestive heart failure severity24 and mortality,25 these markers may also be elevated in the presence of asymptomatic left ventricular dysfunction, the most powerful predictor of SCD risk.
Several limitations of the present study warrant consideration. First, our analysis was based on a single baseline determination of each plasma marker; therefore, we were unable to account for changes in these markers over time. In addition, because most of the events occurred later in the study, we were limited in our ability to assess the effects on short-term risk. This limitation could account for the relatively null results observed for lipid parameters and homocysteine if the majority of their effects are on short-term risk or if the levels changed significantly over the course of the study because of changes in dietary habits and/or the use of lipid-lowering agents. For example, in this same cohort, homocysteine levels were associated with MI over the short term16 but not over a longer follow-up period.26 Finally, even though the present study is the largest we know of to examine the association between these plasma markers and the risk of SCD in apparently healthy men, our power to detect small to moderate effects is still limited by the small number of cases. This may account for the absence of a statistically significant association between TC/HDL-C and SCD.
In summary, these prospective data suggest that CRP levels may be useful indicators of long-term risk of SCD in apparently healthy men. These data are in agreement with those for other atherosclerotic end points,5–7,19 and together, they support a role for CRP in the assessment of cardiovascular risk in healthy populations.27 This assessment of risk may be particularly important in reducing mortality from SCD. Because more than half of all SCDs occur as the first manifestation of ischemic heart disease3 and because survival rates after out-of-hospital cardiac arrest continue to be poor,28 improved identification of those at risk before the event is crucial. CRP, when used in combination with other cardiac risk factors, may improve the prediction of risk among apparently healthy individuals.
|
Acknowledgments |
|---|
This study was supported by grants (HL-63293 and HL-58755) from the National Institutes of Health and by the Doris Duke Charitable Foundation. Dr Albert was supported by a Mentored Clinical Scientist Development Award from the National Heart, Lung, and Blood Institute (1-K08-HL-03783).
|
Footnotes |
|---|
Dr Ridker is named as a coinventor on patents related to the use of inflammatory biomarkers in cardiovascular disease.
Received January 18, 2002; revision received March 26, 2002; accepted March 26, 2002.
|
References |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
1. American Heart Association. Heart and Stroke Facts: 1995 Statistical Supplement. Dallas, Tex: American Heart Association; 1995.
2. Kannel WB, Cupples LA, D’Agostino RB. Sudden death risk in overt coronary heart disease: the Framingham Study. Am Heart J. 1987; 113: 799–804.[CrossRef][Medline] [Order article via Infotrieve]
3. Kannel WB, Schatzkin A. Sudden death: lessons from subsets in population studies. J Am Coll Cardiol. 1985; 5: 141B–149B.
4. Kannel WB, Wilson PWF, D’Agostino RB, et al. Sudden coronary death in women. Am Heart J. 1998; 136: 205–212.[CrossRef][Medline] [Order article via Infotrieve]
5.
Kuller LH, Tracy RP, Shaten J, et al. Relationship of C-reactive protein and coronary heart disease in the MRFIT nested case-control study: Multiple Risk Factor Intervention Trial. Am J Epidemiol. 1996; 144: 537–547.
6.
Ridker PM, Cushman M, Stampfer MJ, et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 1997; 336: 973–979.
7.
Ridker PM, Hennekens CH, Buring JE, et al. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 2000; 342: 836–843.
8.
Eikelboom JW. Lonn E, Genest JJr, et al. Homocysteine and cardiovascular disease: a critical review of the epidemiologic evidence. Ann Intern Med. 1999; 131: 363–375.
9. Kuller L, Lilienfeld A, Fisher R. An epidemiological study of sudden and unexpected deaths in adults. Medicine. 1967; 46: 341–361.[Medline] [Order article via Infotrieve]
10. Manfredini R, Portaluppi F, Grandi E, et al. Out-of-hospital sudden death referring to an emergency department. Epidemiol. 1996; 49: 865–868.
11. Davies MJ, Thomas A. Thrombosis and acute coronary-artery lesions in sudden cardiac ischemic death. N Engl J Med. 1984; 310: 1137–1140.[Abstract]
12.
Burke AP, Farb A, Malcom GT, et al. Coronary risk factors and plaque morphology in men with coronary disease who died suddenly. N Engl J Med. 1997; 336: 1276–1282.
13. Myerburg RJ. Sudden cardiac death: exploring the limits of our knowledge. J Cardiovasc Electrophysiol. 2001; 12: 369–381.[CrossRef][Medline] [Order article via Infotrieve]
14. The Steering Committee of the Physicians’ Health Study Research Group. Final report on the aspirin component of the ongoing Physicians’ Health Study. N Engl J Med. 1989; 321: 129–135.[Abstract]
15.
Hinkle LE, Thaler HT. Clinical classification of cardiac deaths. Circulation. 1982; 65: 457–464.
16.
Stampfer MJ, Malinow MR, Willett WC, et al. A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians. JAMA. 1992; 268: 877–881.
17.
Rifai N, Tracy RP, Ridker PM. Clinical efficacy of an automated high-sensitivity C-reactive protein assay. Clin Chem. 1999; 45: 2136–2141.
18.
Yu HH, Joubran R, Asmi M, et al. Agreement among four homocysteine assays and results in patients with coronary atherosclerosis and controls. Clin Chem. 2000; 46: 258–264.
19.
Ridker PM, Stampfer MJ, Rifai N, et al. Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease. JAMA. 2001; 285: 2481–2485.
20.
Thompson SG, Kienast J, Pyke SD, et al. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris: European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. N Engl J of Med. 1995; 332: 635–641.
21.
Bruins P, te Velthuis H, Yazdanbakhsh AP, et al. Activation of the complement system during and after cardiopulmonary bypass surgery: postsurgery activation involves C-reactive protein and is associated with postoperative arrhythmia. Circulation. 1997; 96: 3542–3548.
22.
Chung MK, Martin DO, Sprecher D, et al. C-reactive protein elevation in patients with atrial arrhythmias: inflammatory mechanisms and persistence of atrial fibrillation. Circulation. 2001; 104: 2886–2891.
23. Lecomte D, Fornes P, Fouret P, et al. Isolated myocardial fibrosis as a cause of sudden cardiac death and its possible relation to myocarditis. J Forensic Sci. 1993; 38: 617–621.[Medline] [Order article via Infotrieve]
24. Torre-Amione G, Kapadia S, Benedict C, et al. Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the Studies of Left Ventricular Dysfunction (SOLVD). J Am Coll Cardiol. 1996; 27: 1201–1206.[Abstract]
25.
Anita D, Petersen NJ, Feldman AM, et al. Cytokines and cytokine receptors in advanced heart failure: an analysis of the cytokine database from the Vesnarinone Trial (VEST). Circulation. 2001; 103: 2055–2059.
26. Chasan-Taber L, Selhub J, Rosenberg IH, et al. A prospective study of folate and vitamin B6 and risk of myocardial infarction in US physicians. J Am Coll Nutr. 1996; 15: 136–143.[Abstract]
27.
Ridker PM. High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Circulation. 2001; 103: 1813–1818.
28. Ornato JP, Om A. Community experience in treating out-of-hospital cardiac arrest. In: Akhtar M, Myerburg RJ, Ruskin JN, eds. Sudden Cardiac Death. Baltimore, Md: Williams and Wilkins; 1994: 450–462.
This article has been cited by other articles:
 |
|
 |
|
  S. S. Chugh and K. Reinier Predicting Sudden Death in the General Population: Another Step, N Terminal B-Type Natriuretic Factor Levels Circulation, June 9, 2009; 119(22): 2863 - 2864. [Full Text] [PDF]
|
|
|
|
|
|
E. C. Korngold, J. L. Januzzi Jr, M. L. Gantzer, M.V. Moorthy, N. R. Cook, and C. M. Albert Amino-Terminal Pro-B-Type Natriuretic Peptide and High-Sensitivity C-Reactive Protein as Predictors of Sudden Cardiac Death Among Women Circulation, June 9, 2009; 119(22): 2868 - 2876. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Cirillo, Y. Y. Sautin, J. Kanellis, D.-H. Kang, L. Gesualdo, T. Nakagawa, and R. J. Johnson Systemic inflammation, metabolic syndrome and progressive renal disease Nephrol. Dial. Transplant., May 1, 2009; 24(5): 1384 - 1387. [Full Text] [PDF]
|
|
|
|
 |
|
 W. S. Harris, D. Mozaffarian, M. Lefevre, C. D. Toner, J. Colombo, S. C. Cunnane, J. M. Holden, D. M. Klurfeld, M. C. Morris, and J. Whelan Towards Establishing Dietary Reference Intakes for Eicosapentaenoic and Docosahexaenoic Acids J. Nutr., April 1, 2009; 139(4): 804S - 819S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Genovesi, M. G. Valsecchi, E. Rossi, D. Pogliani, I. Acquistapace, V. De Cristofaro, A. Stella, and A. Vincenti Sudden death and associated factors in a historical cohort of chronic haemodialysis patients Nephrol. Dial. Transplant., March 16, 2009; (2009) gfp104v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. S. Moshal, M. Kumar, N. Tyagi, P. K. Mishra, N. Metreveli, W. E. Rodriguez, and S. C. Tyagi Restoration of contractility in hyperhomocysteinemia by cardiac-specific deletion of NMDA-R1 Am J Physiol Heart Circ Physiol, March 1, 2009; 296(3): H887 - H892. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. M Ridker C-Reactive Protein: Eighty Years from Discovery to Emergence as a Major Risk Marker for Cardiovascular Disease Clin. Chem., February 1, 2009; 55(2): 209 - 215. [Full Text] [PDF]
|
|
|
|
|
|
H. Ashrafian, C. W. le Roux, A. Darzi, and T. Athanasiou Effects of Bariatric Surgery on Cardiovascular Function Circulation, November 11, 2008; 118(20): 2091 - 2102. [Full Text] [PDF]
|
|
|
|
 |
|
 L. L. Humphrey, R. Fu, K. Rogers, M. Freeman, and M. Helfand Homocysteine Level and Coronary Heart Disease Incidence: A Systematic Review and Meta-analysis Mayo Clin. Proc., November 1, 2008; 83(11): 1203 - 1212. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. S Harris The omega-3 index as a risk factor for coronary heart disease Am. J. Clinical Nutrition, June 1, 2008; 87(6): 1997S - 2002S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S.-F. Wung and B. E. Aouizerat Candidate Genes of the 5-Lipoxygenase Pathway in Acute Coronary Syndrome: A Pilot Study Biol Res Nurs, April 1, 2008; 9(4): 280 - 292. [Abstract] [PDF]
|
|
|
|
|
|
P. M Ridker High-Sensitivity C-Reactive Protein as a Predictor of All-Cause Mortality: Implications for Research and Patient Care Clin. Chem., February 1, 2008; 54(2): 234 - 237. [Full Text] [PDF]
|
|
|
|
 |
|
 H. Blangy, N. Sadoul, B. Dousset, A. Radauceanu, R. Fay, E. Aliot, and F. Zannad Serum BNP, hs-C-reactive protein, procollagen to assess the risk of ventricular tachycardia in ICD recipients after myocardial infarction Europace, September 1, 2007; 9(9): 724 - 729. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. A. Lawson, K. K. Miller, V. A. Mathur, M. Misra, E. Meenaghan, D. B. Herzog, and A. Klibanski Hormonal and Nutritional Effects on Cardiovascular Risk Markers in Young Women J. Clin. Endocrinol. Metab., August 1, 2007; 92(8): 3089 - 3094. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Ramzy, V. Rao, L. C. Tumiati, N. Xu, R. Sheshgiri, J. Jackman, D. H. Delgado, and H. J. Ross Endothelin-1 accentuates the proatherosclerotic effects associated with C-reactive protein J. Thorac. Cardiovasc. Surg., May 1, 2007; 133(5): 1137 - 1146. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. A. Lanza, D. Pitocco, E. P. Navarese, A. Sestito, G. A. Sgueglia, A. Manto, F. Infusino, T. Musella, G. Ghirlanda, and F. Crea Association between cardiac autonomic dysfunction and inflammation in type 1 diabetic patients: effect of beta-blockade Eur. Heart J., April 1, 2007; 28(7): 814 - 820. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. Schlager, M. Exner, W. Mlekusch, S. Sabeti, J. Amighi, P. Dick, O. Wagner, R. Koppensteiner, E. Minar, and M. Schillinger C-Reactive Protein Predicts Future Cardiovascular Events in Patients With Carotid Stenosis Stroke, April 1, 2007; 38(4): 1263 - 1268. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. Mittleman A 39-year-old woman with hypercholesterolemia. JAMA, July 19, 2006; 296(3): 319 - 326. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Virmani, A. P. Burke, A. Farb, and F. D. Kolodgie Pathology of the vulnerable plaque. J. Am. Coll. Cardiol., April 18, 2006; 47(8 Suppl): C13 - C18. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Mozaffarian, M. B. Katan, A. Ascherio, M. J. Stampfer, and W. C. Willett Trans Fatty Acids and Cardiovascular Disease N. Engl. J. Med., April 13, 2006; 354(15): 1601 - 1613. [Full Text] [PDF]
|
|
|
|
 |
|
 K. W.J. Lee, J. S. Hill, K. R. Walley, and J. J. Frohlich Relative value of multiple plasma biomarkers as risk factors for coronary artery disease and death in an angiography cohort. Can. Med. Assoc. J., February 14, 2006; 174(4): 461 - 466. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A Verma, F Kilicaslan, D O Martin, S Minor, R Starling, N F Marrouche, S Almahammed, O M Wazni, S Duggal, R Zuzek, et al. Preimplantation B-type natriuretic peptide concentration is an independent predictor of future appropriate implantable defibrillator therapies Heart, February 1, 2006; 92(2): 190 - 195. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Mineo, A. K. Gormley, I. S. Yuhanna, S. Osborne-Lawrence, L. L. Gibson, L. Hahner, R. V. Shohet, S. Black, J. E. Salmon, D. Samols, et al. Fc{gamma}RIIB Mediates C-Reactive Protein Inhibition of Endothelial NO Synthase Circ. Res., November 25, 2005; 97(11): 1124 - 1131. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L M Biasucci, G Giubilato, F Graziani, and M Piro CRP is or is not a reliable marker of ischaemic heart disease? Lupus, September 1, 2005; 14(9): 752 - 755. [Abstract] [PDF]
|
|
|
|
|
|
A. Khera, D. K. McGuire, S. A. Murphy, H. G. Stanek, S. R. Das, W. Vongpatanasin, F. H. Wians Jr, S. M. Grundy, and J. A. de Lemos Race and Gender Differences in C-Reactive Protein Levels J. Am. Coll. Cardiol., August 2, 2005; 46(3): 464 - 469. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Thorgeirsson, G. Thorgeirsson, H. Sigvaldason, and J. Witteman Risk factors for out-of-hospital cardiac arrest: the Reykjavik Study Eur. Heart J., August 1, 2005; 26(15): 1499 - 1505. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Liu, S. Wang, A. Deb, K. A. Nath, Z. S. Katusic, J. P. McConnell, and N. M. Caplice Proapoptotic, Antimigratory, Antiproliferative, and Antiangiogenic Effects of Commercial C-Reactive Protein on Various Human Endothelial Cell Types In Vitro: Implications of Contaminating Presence of Sodium Azide in Commercial Preparation Circ. Res., July 22, 2005; 97(2): 135 - 143. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Schillinger, M. Exner, W. Mlekusch, S. Sabeti, J. Amighi, R. Nikowitsch, E. Timmel, B. Kickinger, C. Minar, M. Pones, et al. Inflammation and Carotid Artery--Risk for Atherosclerosis Study (ICARAS) Circulation, May 3, 2005; 111(17): 2203 - 2209. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Nemmar, B. Nemery, P. H. M. Hoet, N. Van Rooijen, and M. F. Hoylaerts Silica Particles Enhance Peripheral Thrombosis: Key Role of Lung Macrophage-Neutrophil Cross-Talk Am. J. Respir. Crit. Care Med., April 15, 2005; 171(8): 872 - 879. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Teng, M. Wolf, M. N. Ofsthun, J. M. Lazarus, M. A. Hernan, C. A. Camargo Jr, and R. Thadhani Activated Injectable Vitamin D and Hemodialysis Survival: A Historical Cohort Study J. Am. Soc. Nephrol., April 1, 2005; 16(4): 1115 - 1125. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. M. Stuveling, S. J. L. Bakker, H. L. Hillege, P. E. de Jong, R. O. B. Gans, and D. de Zeeuw Biochemical risk markers: a novel area for better prediction of renal risk? Nephrol. Dial. Transplant., March 1, 2005; 20(3): 497 - 508. [Full Text] [PDF]
|
|
|
|
|
|
I. J. Kullo and C. M. Ballantyne Conditional Risk Factors for Atherosclerosis Mayo Clin. Proc., February 1, 2005; 80(2): 219 - 230. [Abstract] [PDF]
|
|
|
|
|
|
G. L. Myers, N. Rifai, R. P. Tracy, W. L. Roberts, R. W. Alexander, L. M. Biasucci, J. D. Catravas, T. G. Cole, G. R. Cooper, B. V. Khan, et al. CDC/AHA Workshop on Markers of Inflammation and Cardiovascular Disease: Application to Clinical and Public Health Practice: Report From the Laboratory Science Discussion Group Circulation, December 21, 2004; 110(25): e545 - e549. [Full Text] [PDF]
|
|
|
|
|
|
S. C. Smith Jr, J. L. Anderson, R. O. Cannon III, Y. Y. Fadl, W. Koenig, P. Libby, S. E. Lipshultz, G. A. Mensah, P. M Ridker, and R. Rosenson CDC/AHA Workshop on Markers of Inflammation and Cardiovascular Disease: Application to Clinical and Public Health Practice: Report From the Clinical Practice Discussion Group Circulation, December 21, 2004; 110(25): e550 - e553. [Full Text] [PDF]
|
|
|
|
|
|
S. P. Fortmann, E. Ford, M. H. Criqui, A. R. Folsom, T. B. Harris, Y. Hong, T. A. Pearson, D. Siscovick, F. Vinicor, and P. F. Wilson CDC/AHA Workshop on Markers of Inflammation and Cardiovascular Disease: Application to Clinical and Public Health Practice: Report From the Population Science Discussion Group Circulation, December 21, 2004; 110(25): e554 - e559. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. M. Biasucci CDC/AHA Workshop on Markers of Inflammation and Cardiovascular Disease: Application to Clinical and Public Health Practice: Clinical Use of Inflammatory Markers in Patients With Cardiovascular Diseases: A Background Paper Circulation, December 21, 2004; 110(25): e560 - e567. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. F. Tomaselli and D. P. Zipes What Causes Sudden Death in Heart Failure? Circ. Res., October 15, 2004; 95(8): 754 - 763. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Engstrom, B. Hedblad, L. Stavenow, P. Tyden, P. Lind, L. Janzon, and F. Lindgarde Fatality of Future Coronary Events Is Related to Inflammation-Sensitive Plasma Proteins: A Population-Based Prospective Cohort Study Circulation, July 6, 2004; 110(1): 27 - 31. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Paoletti, C. Specchia, G. Di Maio, D. Bellino, B. Damasio, P. Cassottana, and G. Cannella The worsening of left ventricular hypertrophy is the strongest predictor of sudden cardiac death in haemodialysis patients: a 10 year survey Nephrol. Dial. Transplant., July 1, 2004; 19(7): 1829 - 1834. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. T. Willerson and P. M. Ridker Inflammation as a Cardiovascular Risk Factor Circulation, June 1, 2004; 109(21_suppl_1): II-2 - II-10. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Verma, P. E. Szmitko, and E. T.H. Yeh C-Reactive Protein: Structure Affects Function Circulation, April 27, 2004; 109(16): 1914 - 1917. [Full Text] [PDF]
|
|
|
|
|
|
T. J. Bunch, K. Chandrasekaran, B. J. Gersh, S. C. Hammill, D. O. Hodge, A. H. Khan, D. L. Packer, and P. A. Pellikka The prognostic significance of exercise-induced atrial arrhythmias J. Am. Coll. Cardiol., April 7, 2004; 43(7): 1236 - 1240. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M Backes, P. A Howard, and P. M Moriarty Role of C-Reactive Protein in Cardiovascular Disease Ann. Pharmacother., January 1, 2004; 38(1): 110 - 118. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. J. Blake, N. Rifai, J. E. Buring, and P. M Ridker Blood Pressure, C-Reactive Protein, and Risk of Future Cardiovascular Events Circulation, December 16, 2003; 108(24): 2993 - 2999. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. M Ridker and on behalf of the JUPITER Study Group Rosuvastatin in the Primary Prevention of Cardiovascular Disease Among Patients With Low Levels of Low-Density Lipoprotein Cholesterol and Elevated High-Sensitivity C-Reactive Protein: Rationale and Design of the JUPITER Trial* Circulation, November 11, 2003; 108(19): 2292 - 2297. [Full Text] [PDF]
|
|
|
|
|
|
M. Schillinger, M. Exner, J. Amighi, W. Mlekusch, S. Sabeti, H. Rumpold, O. Wagner, and E. Minar Joint Effects of C-Reactive Protein and Glycated Hemoglobin in Predicting Future Cardiovascular Events of Patients With Advanced Atherosclerosis Circulation, November 11, 2003; 108(19): 2323 - 2328. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H S Gurm, D L Bhatt, A M Lincoff, J E Tcheng, D J Kereiakes, N S Kleiman, G Jia, and E J Topol Impact of preprocedural white blood cell count on long term mortality after percutaneous coronary intervention: insights from the EPIC, EPILOG, and EPISTENT trials Heart, October 1, 2003; 89(10): 1200 - 1204. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Chandalia, A. V. Cabo-Chan Jr, S. Devaraj, I. Jialal, S. M. Grundy, and N. Abate Elevated Plasma High-Sensitivity C-Reactive Protein Concentrations in Asian Indians Living in the United States J. Clin. Endocrinol. Metab., August 1, 2003; 88(8): 3773 - 3776. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. B. Ledue and N. Rifai Preanalytic and Analytic Sources of Variations in C-reactive Protein Measurement: Implications for Cardiovascular Disease Risk Assessment Clin. Chem., August 1, 2003; 49(8): 1258 - 1271. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. V. Huikuri, T. H. Makikallio, M. J. P. Raatikainen, J. Perkiomaki, A. Castellanos, and R. J. Myerburg Prediction of Sudden Cardiac Death: Appraisal of the Studies and Methods Assessing the Risk of Sudden Arrhythmic Death Circulation, July 8, 2003; 108(1): 110 - 115. [Full Text] [PDF]
|
|
|
|
|
|
R. C. Pasternak, J. Abrams, P. Greenland, L. A. Smaha, P. W. F. Wilson, and N. Houston-Miller Task force #1--identification of coronary heart disease risk: is there a detection gap? J. Am. Coll. Cardiol., June 4, 2003; 41(11): 1863 - 1874. [Full Text] [PDF]
|
|
|
|
|
|
C.-H. Wang, S.-H. Li, R. D. Weisel, P. W.M. Fedak, A. S. Dumont, P. Szmitko, R.-K. Li, D. A.G. Mickle, and S. Verma C-Reactive Protein Upregulates Angiotensin Type 1 Receptors in Vascular Smooth Muscle Circulation, April 8, 2003; 107(13): 1783 - 1790. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. W. Chan, D. L. Bhatt, D. P. Chew, J. Reginelli, J. P. Schneider, E. J. Topol, and S. G. Ellis Relation of Inflammation and Benefit of Statins After Percutaneous Coronary Interventions Circulation, April 8, 2003; 107(13): 1750 - 1756. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Rifai and P. M. Ridker Population Distributions of C-reactive Protein in Apparently Healthy Men and Women in the United States: Implication for Clinical Interpretation Clin. Chem., April 1, 2003; 49(4): 666 - 669. [Full Text] [PDF]
|
|
|
|
|
|
P. M Ridker Clinical Application of C-Reactive Protein for Cardiovascular Disease Detection and Prevention Circulation, January 28, 2003; 107(3): 363 - 369. [Full Text] [PDF]
|
|
|
|
|
|
T. A. Pearson, G. A. Mensah, R. W. Alexander, J. L. Anderson, R. O. Cannon III, M. Criqui, Y. Y. Fadl, S. P. Fortmann, Y. Hong, G. L. Myers, et al. Markers of Inflammation and Cardiovascular Disease: Application to Clinical and Public Health Practice: A Statement for Healthcare Professionals From the Centers for Disease Control and Prevention and the American Heart Association Circulation, January 28, 2003; 107(3): 499 - 511. [Full Text] [PDF]
|
|
|
|
 |
|
 A. De Bree, W. M. Verschuren, D. Kromhout, L. I Mennen, H. J Blom, E. S Ford, S J. Smith, D. F Stroup, K. K Steinberg, P. W Mueller, et al. Homocysteine and coronary heart disease: the importance of a distinction between low and high risk subjects Int. J. Epidemiol., December 1, 2002; 31(6): 1268 - 1272. [Full Text] [PDF]
|
|
|
|
|
|
P. M. Ridker, N. Rifai, L. Rose, J. E. Buring, and N. R. Cook Comparison of C-Reactive Protein and Low-Density Lipoprotein Cholesterol Levels in the Prediction of First Cardiovascular Events N. Engl. J. Med., November 14, 2002; 347(20): 1557 - 1565. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. J. Blake and P. M. Ridker C-Reactive Protein, Subclinical Atherosclerosis, and Risk of Cardiovascular Events Arterioscler. Thromb. Vasc. Biol., October 1, 2002; 22(10): 1512 - 1513. [Full Text] [PDF]
|
|
|
|
|
|
P. M. Spooner and D. P. Zipes Sudden Death Predictors: An Inflammatory Association Circulation, June 4, 2002; 105(22): 2574 - 2576. [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||